Vetoquinol: Availability of the 2022 Universal Registration Document

Regulatory News:

On 13 April 2023, Vetoquinol (Paris:VETO) filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

The 2022 Universal Registration Document in ESEF and PDF formats (reproduction of the official version of the Universal Registration Document in ESEF format) is available to the public under the conditions provided by applicable regulations and may be consulted on the “Investors” page of the Vetoquinol laboratory website (www.vetoquinol.com), in the “Regulated Information” section. It is also available on the AMF’s website (www.amf-france.org).

The 2022 Universal Registration Document includes:

• the 2022 Annual Financial Report;
• the Management Report;
• the Board of Directors Report on Corporate Governance;
• the Extra-Financial Performance Declaration;
• the information related to the fees paid to the Statutory Auditors;
• the share buyback program description; and
• the agenda and draft resolutions of the Shareholder’s Meeting of May 25th, 2023.

Next update: Shareholder’s Meeting, May 25th, 2023

ABOUT VETOQUINOL Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the farm animals (cattle and pigs) and pets (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,521 people as of December 31st, 2022. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO). The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005623/en/

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations Fanny Toillon Tel.: [phone] [e-mail]

KEIMA COMMUNICATION

Investor & Media Relations Emmanuel Dovergne Tel.: [phone] [e-mail]